Interventions for Tuberculosis Control and Elimination 2002

326. Kannapiran M, Krishnamurthy PV, Raghupatti Sarma G. Uric acid disposition
during intermittent chemotherapy of pulmonary tuberculosis with regimens containing
pyrazinamide and rifampicin. Indian J Med Res 1985; 82: 116-21.
327. Ellard GA, Haslam RM. Observations on the reduction of the renal elimination
of urate in man caused by the administration of pyrazinamide.
57: 97-103.
Tubercle 1976;
328. Radal M, Jonville-Béra AP, Van-Egroo C, Carré P, Lemarié E, Autret E. Eruption
après la première prise d’une chimiothérapie standard antituberculeuse. Penser
au pyrazinamide. Rev Mal Resp 1998; 15: 305-6.
329. Olivier C, Radal M, Mazaud S, Jonville-Béra AP, Martel C, Autret E. Eruption
après une première prise d’une quadrithérapie antituberculeuse: penser au pyrazinamide.
Arch Pédiatr 1998; 5: 289-90.
330. Layer P, Engelhard M. Tuberkulostatika-induzierter systemischer Lupus erythematodes.
Dtsch Med Wschr 1986; 111: 1603-5.
331. Herlevsen P, Nielsen C, Thuesen Pedersen J. Convulsions after treatment with
pyrazinamide. Tubercle 1987; 68: 145-6.
332. Choohakarn C, Janma J. Pyrazinamide-induced lichenoid photodermatitis.
(Correspondence). J Am Acad Dermatol 1999; 40: 645-6.
333. Lacroix C, Guyonnaud C, Chaou M, Duwoos H, Lafont O. Interaction between
allopurinol and pyrazinamide. Eur Respir J 1988; 1: 807-11.
334. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR,
McGuiness ME, Berning SE, Gerena G. Low antituberculosis drug concentrations
in patients with AIDS. Ann Pharmacother 1996; 30: 919-25.
335. Fox IH, Stein HB, Gershon SL. Effects of vitamins on the renal handling of
uric acid. Adv Exp Med Biol 1977; 76B: 30-5.
336. Manuel MA, Steele TH. Pyrazinamide suppression of the uricosuric response to
sodium chloride infusion. J Lab Clin Med 1967; 83: 417-27.
337. Wilkinson RG, Shepherd RG, Thomas JP, Baughn C. Stereospecificity in a new
type of synthetic antituberculous agent.
1961; 83: 2212-3.
(Correspondence). J Am Chem Soc
338. Thomas JP, Baughn CO, Wilkinson RG, Shepherd RG. A new synthetic compound
with antituberclous activity in mice: ethambutol (dextro-2,2’-(ethylenediimino)-di-1-butanol).
Am Rev Respir Dis 1961; 83: 891-3.
339. Karlson AG. Therapeutic effect of ethambutol (dextro-2,2’-[ethylene-diimino]di-1-butanol)
on experimental tuberculosis in guinea pigs.
1961; 84: 902-4.
Am Rev Respir Dis
340. Karlson AG. The in vitro activity of ethambutol (dextro-2,2’-[ethylene-diimino]di-1-butanol)
against tubercle bacilli and other microorganisms. Am Rev Respir
Dis 1961; 84: 905-6.
191